Jemperli a Key Oncology Drug for GSK In the first nine months of 2024, Jemperli recorded sales worth £318 million. Sales of the drug are being driven by new patient starts in the United States.

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions for the ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

GSK's strengths today are its HIV business ... thanks to recently approved meds Jemperli and Ojjara, indicated for solid tumor cancers and myelofibrosis respectively, a >$3bn per annum immuno ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical ... In oncology, while PARP inhibitors remain relatively static, Jemperli shows promising growth, particularly in endometrial cancer ...

GSK’s application is underpinned by the positive ... In January 2025, the European Commission approved the company’s Jemperli in conjunction with chemotherapy for the first-line treatment ...